Celltrion Posts 430 Billion Won Q2 Operating Profit, Beats Consensus by 8% Despite Stock Target Cut

According to Economist, Celltrion posted operating profit of 430 billion won in Q2 on July 6, up 77% year-over-year and exceeding market consensus by 8%. Revenue reached 1.3 trillion won, up 35% annually. However, Korean securities firms lowered the company's stock price target to 2.6 million won, citing weakness in the broader domestic biotech sector rather than company fundamentals. Operating margin improved to 33% as sales of new biosimilars like Remsima SC and Omniclone expanded. Securities analysts expect continued growth in the second half, with new product launches in the U.S. market and expanded European indications for Stekimla anticipated to drive revenue and profitability gains.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments